Last Update Time:
17-Mar-2025 16:00:00
ISIN:
INE416D01022
Sector:
Healthcare
Symbol:
BLISSGVS
Bliss GVS Pharma Limited
₹112.00
₹-2.29
(-2.00%)
▼
Prev. Close
₹114.29
Open
₹115.00
Close
₹0.00
Range
₹106.40 - ₹117.60
High
₹116.37
Low
₹111.80
Ind. Close
₹0.00
VWAP
₹113.97
The current stock price of Bliss GVS Pharma Limited is ₹112.00, with a target price range between ₹106.40 and ₹117.60. The stock has experienced a price change of ₹-2.29 (-2.00%), reflecting recent market volatility.
Today's opening price was ₹115.00, while the previous close stood at ₹114.29.
The market trend suggests a potential downtrend, with investors exercising caution due to recent declines. Analysts recommend closely monitoring support levels.
For real-time stock market updates, live share prices, and stock analysis, stay tuned. Understanding key stock metrics like VWAP, high-low range, and market momentum can help traders make informed investment decisions.
Bliss GVS Pharma Limited Price Chart
Bliss GVS Pharma Limited Pre Open Market Overview: 17-Mar-2025
Key Metrics:
- IEP (Indicative Equilibrium Price): 115
- Previous Close Price: 114.29
- Change: 0.71%
- Total Traded Volume: 401
- Total Buy Quantity: 10,725
- Total Sell Quantity: 25,397
| Price | Buy Qty | Sell Qty |
|---|---|---|
| 114.00 | 225.00 | 0.00 |
| 114.11 | 300.00 | 0.00 |
| 114.29 | 1.00 | 0.00 |
| 114.86 | 100.00 | 0.00 |
| 115.00 | 207.00 | 0.00 |
| 115.35 | 0.00 | 5.00 |
| 115.95 | 0.00 | 39.00 |
| 115.99 | 0.00 | 1.00 |
| 116.00 | 0.00 | 10.00 |
| 116.49 | 0.00 | 1.00 |
ATO Data:
- Buy Quantity (ATO): 0
- Sell Quantity (ATO): 0
Order Book
| Bid | Qty | Ask | Qty |
|---|---|---|---|
| 0.00 | 0 | 112.41 | 763 |
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
Total Buy Quantity: 10725
Total Sell Quantity: 25397
Shareholding Patterns of Bliss GVS Pharma Limited
Key Trade Statistics of Bliss GVS Pharma Limited
| Trade Information | Details |
|---|---|
| Traded Volume (Lakhs) | 5.07 |
| Traded Value (₹ Cr.) | 5.77 |
| Total Market Cap (₹ Cr.) | 1,180.15 |
| Free Float Market Cap (₹ Cr.) | 735.99 |
| Impact cost | 0.12 |
| Quantity Traded | 458,851.00 |
| Deliverable Quantity | 331,049.00 |
| % of Quantity to Traded | 72.15 |
| Security VaR | 22.96 |
| Index VaR | N/A |
| VaR Margin | 22.96 |
| Extreme Loss Rate | 3.5 |
| Adhoc Margin | N/A |
| Applicable Margin Rate | 26.46 |
| Face Value | 1 |
Key Price Statistics of Bliss GVS Pharma Limited
The 52-week high for Bliss GVS Pharma Limited was ₹185.50, recorded on 03-Jan-2025. On the other hand, the 52-week low stands at ₹92.15, with the lowest value recorded on 04-Jun-2024.
The upper band for trading is ₹137.14, and the lower band is ₹91.43. The price band is 20%.
The stock's daily volatility stands at 3.45, while the annualized volatility is 65.91. The tick size for trading is ₹0.01.
| Price Information | Details |
|---|---|
| 52 Week High (03-Jan-2025) | 185.50 |
| 52 Week Low (04-Jun-2024) | 92.15 |
| Upper Band | 137.14 |
| Lower Band | 91.43 |
| Price Band (%) | 20 |
| Daily Volatility | 3.45 |
| Annualised Volatility | 65.91 |
| Tick Size | 0.01 |
Key Securities Statistics of Bliss GVS Pharma Limited
| Securities Information | Details |
|---|---|
| Status | Listed |
| Trading Status | Active |
| Date of Listing | 26-Jul-2010 |
| Adjusted P/E | 7.52 |
| Symbol P/E | 17.53 |
| Index | NA |
| Macro-Economic Sector | Healthcare |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Basic Industry | Pharmaceuticals |
Security Status of Bliss GVS Pharma Limited
| Title | Details |
|---|---|
| Board Status | Main |
| Trading Segment | Normal Market |
| Session No. | - |
| Class of Shares | Equity |
| SDD Compliance | - |
| Name of Compliance Officer | - |
Announcements of Bliss GVS Pharma Limited
| Subject | Date |
|---|---|
| Integrated Filing- Financial | 30-Jan-2025 |
| Copy of Newspaper Publication | 30-Jan-2025 |
| Certificate under SEBI (Depositories and Participants) Regulations, 2018 | 29-Jan-2025 |
| Outcome of Board Meeting | 28-Jan-2025 |
| Financial Result Updates | 28-Jan-2025 |
| Board Meeting Intimation | 21-Jan-2025 |
| Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent | 16-Jan-2025 |
| Change in Management | 16-Jan-2025 |
Corporate Actions of Bliss GVS Pharma Limited
| Face Value | Purpose | Ex-Date |
|---|---|---|
| 1 | Annual General Meeting/Dividend - Rs 0.50 Per Share | 18-Jul-2024 |
| 1 | Annual General Meeting/Dividend - Re 0.50 Per Share | 12-Jul-2023 |
| 1 | Annual General Meeting/ Dividend - Rs 0.50 Per Share | 20-Jun-2022 |
| 1 | Annual General Meeting/Dividend - Rs 0.50 Per Share | 13-Sep-2021 |
| 1 | Annual General Meeting/Dividend - Rs 0.50 Per Share | 17-Sep-2020 |
| 1 | Annual General Meeting/Dividend - Re 1 Per Share | 12-Sep-2019 |
| 1 | Annual General Meeting/Dividend- Re 1 Per Share | 14-Aug-2018 |
| 1 | Annual General Meeting/Dividend - Re 0.60 Per Share (Book Closure Dates Revised) | 18-Sep-2017 |
| 1 | Annual General Meeting/Dividend Re 0.50 Per Share | 06-Sep-2016 |
| 1 | Annual General Meeting/ Dividend - Re 0.50/- Per Share (Book Closure Dates Revised) | 08-Sep-2015 |
| 1 | Interim Dividend - Re 0.20 Per Share | 24-Feb-2015 |
| 1 | Annual General Meeting / Final Dividend - Re 0.50/- Per Share | 13-Aug-2014 |
| 1 | Annual General Meeting / Dividend Rs 0.40 Per Share | 01-Aug-2013 |
| 1 | Interim Dividend Rs 0.30 Per Share | 25-Feb-2013 |
| 1 | Annual General Meeting / Dividend Rs 0.40 Per Share | 02-Aug-2012 |
| 1 | Interim Dividend Re.0.35 Per Share | 24-Nov-2011 |
| 1 | Dividend-Re.0.30 Per Share | 14-Jul-2011 |
| 1 | Interim Dividend Re 0.30 Per Share | 25-Nov-2010 |
Board Meetings of Bliss GVS Pharma Limited
Financial Results of Bliss GVS Pharma Limited
Company Directory of Bliss GVS Pharma Limited
| Web Address | Office | Address | City |
|---|---|---|---|
| www.blissgvspharma.com | Registered Office | 102, Hyde Park Saki Vihar Road, Opp. Ansa Industrial Estate Andheri (East) | MUMBAI |
| www.blissgvspharma.com | Transfer Agent | M/s. Universal Capital Securities Private Limited 21, Shakti Niwas, Opp. Satya Saibaba Temple Mahakali Caves Road, Andheri(E), | MUMBAI |
Insider Trading of Bliss GVS Pharma Limited
| Reg. Clause | Acq./Disp. | Sec. Value | Txn Type |
|---|---|---|---|
| 7(2) | Mr. Narsimha Shibroor Kamath | 3072625 | Buy |
| 7(2) | Mr. Narsimha Shibroor Kamath | 9819292 | Buy |
| 7(2) | Narsimha Shibroor Kamath | 20850543 | Buy |
| 7(2) | Narsimha Shibroor Kamath | 24491966 | Buy |
| 7(2) | Vibha Gagan Sharma | 0 | Buy |
| 7(2) | Mr. Narsimha Shibroor Kamath | 23724714 | Buy |
| 7(2) | Narsimha Shibroor Kamath | 7797497 | Buy |
| 7(2) | Narsimha Shibroor Kamath | 15386242 | Buy |
| 7(2) | Vibha Gagan Sharma | 21246696 | Buy |
| 7(2) | Shruti Vishal Rao | 11105806 | Buy |
| 7(2) | Vibha Gagan Sharma | 20669815 | Buy |
| 7(2) | Shruti Vishal Rao | 9469301 | Buy |
| 7(2) | Shruti Vishal Rao | 25531787 | Buy |
| 7(2) | Vibha Gagan Sharma | 25735395 | Buy |
| 7(2) | Narsimha Shibroor Kamath | 200850000 | Sell |
| 7(2) | Vibha Gagan Sharma | 100425000 | Buy |
| 7(2) | Shruti Vishal Rao | 100425000 | Buy |
| 7(2) | Mr. Gautam Rasiklal Ashra | 11123000 | Pledge |
| 7(2) | Mr. Arjun Gautam Ashra | 11123000 | Pledge |
| 7(2) | MANGESH GHANASHYAM WAGLE | 11172020 | Sell |
Annual Reports of Bliss GVS Pharma Limited
Investor Complaints of Bliss GVS Pharma Limited
Event Calendar of Bliss GVS Pharma Limited
| Purpose | Details |
|---|---|
| Results/Dividend | To consider, interalia, the Un-audited Financial Results for the Quarter ended September 30, 2010 & Dividend if any. |
| Results/Dividend | To consider, interalia, the Audited Financial Result for the year ended March 31, 2011 and dividend if any. |
| Results/Dividend | To consider, inter alia, the Un-audited Financial Results for the Quarter ended September 30, 2011 and dividend if any. |
| Results/Dividend | To consider interalia, the Audited Financial Results of the Company for the year ended March 31, 2012 and dividend, if any. |
| Results/Dividend | To Consider interalia, the un-audited Financial Results of the Company for the Quarter ended December 31, 2012 and Dividend if any. |
| Results/Dividend | To consider interalia, the audited Financial Results of the company for the year ended March 31, 2013 and dividend, if any. |
| Results | To consider interalia, the Un-audited Financial Results of the Company for the Quarter ended June 30, 2013. |
| Results | To consider interalia, the Un-audited Financial Results of the Company for the Quarter ended September 30, 2013. |
| Results | To Consider interalia, the un-audited Financial Results of the Company for the Quarter ended December 31, 2013. |
| Results/Dividend | To consider interalia:- (1) The Audited Financial Results of the company for the quarter and year ended March 31, 2014; (2) And dividend, if any. |
| Results | To consider interalia, the Un-audited Financial Results of the Company for the Quarter ended June 30, 2014. |
| Results | Inter-alia to consider the Unaudited Financial Results of the Company for the quarter ended September 30, 2014. |
| Results/Dividend | to consider interalia: 1) The Un-audited Financial Results of the Company for the Quarter ended December 31, 2014. 2) And dividend if any |
| Results/Dividend | To consider interalia, 1. The Audited Financial Results of the Company for the year ended March 31, 2015. 2. Dividend, if any. |
| Results | to consider inter alia the un-audited financial results of the company for the Quarter ended June 30, 2015. |
| Results | To consider inter alia, the Un-Audited Financial Results of the Company tor the quarter ended September 30, 2015. |
| Results | To consider inter alia, the Un-Audited Financial Results of the Company for the quarter and nine months ended December 31, 2015. |
| Results/Dividend | To consider inter alia, the Audited Financial Results of the Company for the quarter and year ended March 31, 2016 and dividend if any. |
| Results | To consider inter alia, the Un-Audited Financial Results of the Company for the quarter ended June 30, 2016. |
| Results | To consider inter alia, the Un-Audited Financial Results of the Company for the quarter and half year ended September 30, 2016. Further, Pursuant to the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulation, 2015 read with the provision of the code of fair disclosure of the Company, the trading window of the Company will be closed from October 18, 2016 to October 29, 2016 (both days inclusive). |
| Results | To consider inter alia, the Un-Audited Standalone and Consolidated Financial Results of the Company for the quarter ended December 31, 2016. |
| Results/Dividend | to consider inter alia, the Audited Standalone and Consolidated Financial Results of the Company for the year ended March 31, 2017 and dividend if any. |
| Results | To consider inter alia, the Unaudited Standalone and Consolidated Financial Results of the Company for the year ended June 30, 2017. |
| Results | to consider inter alia, the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter & half year ended September 30, 2017. |
| Others | for considering disinvestment of subsidiary business. |
| Results | To consider inter alia, the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended December 31, 2017. |
| Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2018 and dividend |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2018 |
| Financial Results | To consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter & half year ended September 30, 2018.Further, pursuant to the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulation, 2015 read with the provision of the code of fair disclosure of the Company, the trading window of the Company will be closed from Thursday, October 25, 2018 to Monday, November 05, 2018 (both days inclusive). Kindly acknowledge and take on record the same. |
| Financial Results/Other business matters | To consider and approve the financial results for the period ended December 31, 2018 and other business matters |
| Other business matters | Pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to intimate you that the Board Meeting of the Company will be held on Monday, February 25, 2019 to consider and approve the following agendas:a) The proposal for establishment of Employee Stock Option Plan scheme;b) Increase in Shareholding limit of Foreign Portfolio Investors in the Company; andc) Re-appointment and continuation of Directorship of Mr. S. R. Vaidya (DIN: 03600249) as an Independent Director of the Company.Kindly acknowledge and take on record the same. |
| Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2019 and dividend |
| Financial Results/Other business matters | To consider and approve the financial results for the period ended Jun 30, 2019 and other business matters |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2019 |
| Financial Results/Other business matters | To consider and approve the financial results for the period ended December 31, 2019 and other business matters |
| Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2020 and dividend |
| Financial Results/Other business matters | To consider and approve the financial results for the period ended Jun 30, 2020 and other business matters |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2020 |
| Financial Results/Other business matters | To consider and approve the financial results for the period ended December 31, 2020 and other business matters |
| Financial Results | To consider and approve the financial results for the period ended March 31, 2021 |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2021 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2021 |
| Financial Results/Other business matters | To consider and approve the financial results for the period ended December 31, 2021 and other business matters |
| Financial results | Bliss GVS Pharma Limited has informed the Exchange about Board Meeting to be held on 30-Apr-2022 to consider financial statements for the period ended March 2022 |
| Financial results | Bliss GVS Pharma Limited has informed the Exchange about Board Meeting to be held on 07-Nov-2022 to consider financial statements for the period ended September 2022 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2022 |
| Financial Results/Other business matters | To consider and approve the financial results for the period ended Jun 30, 2023 and other business matters |
| Financial Results/Other business matters | To consider and approve the financial results for the period ended September 30, 2023 and other business matters |
| Financial Results/Other business matters | To consider and approve the financial results for the period ended December 31, 2023 and other business matters |
| Financial Results/Dividend/Other business matters | To consider and approve the financial results for the period ended March 31, 2024, dividend and other business matters |
| Financial Results/Other business matters | To consider and approve the financial results for the period ended Jun 30, 2024 and other business matters |
| Financial Results/Other business matters | To consider and approve the financial results for the period ended September 30, 2024 and other business matters |
| Financial Results/Other business matters | Inter alia to consider, approve and take on record: 1. The Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31, 2024; and2. The proposal for issuance of Sweat Equity Shares pursuant to applicable provisions of the Companies Act, 2013, the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 and other applicable laws and regulations to Key Managerial Personnel and/or Senior Management Personnel and/or Employee(s) of the Company including determination of the issue price if any, subject to such regulatory and statutory approvals as may be required including approval of the shareholders of the Company. |
Share Transfers of Bliss GVS Pharma Limited
Voting Results of Bliss GVS Pharma Limited
| Date of Mtg. | Mtg. Type | Resolution |
|---|---|---|
| 25-JUL-2024 | AGM | Adoption of Audited Standalone and Consolidated Financial Statements for the financial year ended March 31, 2024 together with the reports of the Board of Directors and the Auditors thereon. |
| 25-JUL-2024 | AGM | Approval for Material Related Party Transaction(s) with Greenlife Pharmaceuticals Limited |
| 25-JUL-2024 | AGM | Re-appointment of Mr. Vishal Vijay Rao as a VicePresident of the Company, a relative of Directors holding office or place of profit in the Company |
| 25-JUL-2024 | AGM | Re-appointment of Ms. Shilpa Bhatia (DIN: 08695595) as an Independent Director of the Company |
| 25-JUL-2024 | AGM | Re-appointment of Mrs. Shruti Vishal Rao (DIN: 00731501) as a Whole-Time Director of the Company |
| 25-JUL-2024 | AGM | Re-appointment of Dr. Vibha Gagan Sharma (DIN: 02307289) as a Whole-Time Director of the Company |
| 25-JUL-2024 | AGM | Re-appointment of Mr. Gagan Harsh Sharma (DIN: 07939421) as a Managing Director of the Company |
| 25-JUL-2024 | AGM | Appointment of Dr. Nandkumar Kashinath Chodankar (DIN: 02736718) as an Independent Director of the Company |
| 25-JUL-2024 | AGM | Re-Appointment of Mrs. Shruti Vishal Rao (DIN: 00731501) as a Director, liable to retire by rotation, who has offered herself for reappointment |
| 25-JUL-2024 | AGM | Declaration of Final Dividend of 50% i.e. Re. 0.50 paisa per equity share on face value of Rs. 1/- each for the financial year ended March 31, 2024. |
| 19-JUL-2023 | AGM | doption of Audited Standalone and Consolidated Financial Statements for the financial year ended March 31, 2023 together with the Reports of the Board of Directors and the Auditors thereon. |
| 19-JUL-2023 | AGM | Approval for Material Related Party Transaction(s) with Greenlife Pharmaceuticals Limited |
| 19-JUL-2023 | AGM | Re-appointment of Dr. Vibha Gagan Sharma (DIN: 02307289) as a Director of the Company, who retires by rotation, and being eligible offered herself for re-appointment. |
| 19-JUL-2023 | AGM | Declaration of Final Dividend of 50% i.e. ￂ 0.50 paisa per equity share on face value of Rs. 1/- each for the financial year ended March 31, 2023. |
| 28-JUN-2022 | AGM | Adoption of Audited Standalone Financial Statements for the year ended March 31, 2022 together with the Reports of the Board of Directors and the Auditors thereon and the Audited Consolidated Financial Statements for the year ended March 31, 2022 and the reports of auditors thereon. |
| 28-JUN-2022 | AGM | Re-appointment of M/s. Kalyaniwalla & Mistry LLP, Chartered Accountants, (FRN.104607W/W10166) as Statutory Auditors of the Company and fix their remuneration. |
| 28-JUN-2022 | AGM | Re-appointment of Mr. Gagan Harsh Sharma (DIN: 07939421) as a Director of the by rotation, and being eligible offered himself Company, who retires for re-appointment. |
| 28-JUN-2022 | AGM | Declaration of Final Dividend of 50% ie. Rs. 0.50 paisa per equity share on face value of Rs. 1/- each for the financial year ended March 31, 2022 |
| 21-SEP-2021 | AGM | Adoption of Audited Standalone Financial Statements for the year ended March 31, 2021 together with the Reports of the Board of Directors and the Auditors thereon and the Audited Consolidated Financial Statements for the year ended March 31, 2021 and the reports of auditors thereon. |
| 21-SEP-2021 | AGM | Declaration of Final Dividend of 50% i.e. ￂ 0.50 paisa per equity share on face value of Rs. 1/- each for the financial year ended March 31, 2021 |
FAQs on Bliss GVS Pharma Limited
Disclaimer: The information provided here is for informational purposes only and should not be considered financial advice. Please do your own research and consult with a financial professional before making any investment decisions.